旨在调查具有种系同源重组修复 (HRR) 基因致病性/可能致病性变异 (PV/LPV) 的无症状携带者中降低风险的输卵管卵巢切除术 (RRSO) 的病理结果和临床结果的患病率。这项回顾性研究纳入了无症状携带者种系HR基因PV/LPV于2006年至2022年间在韩国国家癌症中心接受了RRSO。分析了临床特征，包括乳腺癌病史、卵巢/乳腺癌家族史、产次和口服避孕药的使用情况。 在 255 名接受 RRSO 的女性中，129 名 (50.6%) 患有 BRCA1 中的 PV/LPV，121 名 (47.5 %）存在于 BRCA2 中，2 名（0.7%）同时具有 BRCA1 和 BRCA2 PV/LPV。此外，RAD51D 中有 1 个携带 PV/LPV，BRIP1 中有 2 个携带 PV/LPV。在 BRCA1/2 PV/LPV 携带者中，3.5% 的患者发现隐匿性肿瘤：浆液性输卵管上皮内癌（1.1%，n=3）、输卵管癌（0.8%，n=2）、卵巢癌（1.2%）。 ，n=3）和乳腺癌（0.4%，n=1）。 9例隐匿性肿瘤患者中，178例乳腺癌患者中检出5例（2.0%），65例健康突变携带者中检出4例（1.6%）。在 36.7 个月的中位随访期间（四分位距，25.9-71.4），1 名（0.4%）BRCA1 PV 携带者在 RRSO 处无前驱病变，在 30.1 个月后发展为原发性腹膜癌病。 患有 HRR 基因突变 PV/LPV 的女性接受 RRSO 的人有检测到隐匿性肿瘤的风险，该风险为 3.5%。即使在 RRSO 期间没有出现前驱病变，腹膜癌病发展的累积风险也存在，强调需要持续监测。© 2025。亚洲妇科肿瘤学会、韩国妇科肿瘤学会和日本妇科肿瘤学会。

To investigate the prevalence of pathological findings and clinical outcomes of risk-reducing salpingo-oophorectomy (RRSO) in asymptomatic carriers with germline homologous recombination repair (HRR) gene pathogenic/likely pathogenic variants (PV/LPV).This retrospective study enrolled asymptomatic carriers with germline HR gene PV/LPV who underwent RRSO between 2006 and 2022 at the National Cancer Center in Korea. Clinical characteristics, including history of breast cancer, family history of ovarian/breast cancer, parity, and oral contraceptive use, were analyzed.Of the 255 women who underwent RRSO, 129 (50.6%) had PV/LPV in BRCA1, 121 (47.5%) in BRCA2, and 2 (0.7%) had both BRCA1 and BRCA2 PV/LPV. In addition, 1 carried PV/LPV in RAD51D, and 2 in BRIP1. Among the BRCA1/2 PV/LPV carriers, occult neoplasms were identified in 3.5% of patients: serous tubal intraepithelial carcinoma (1.1%, n=3), fallopian tubal cancers (0.8%, n=2), ovarian cancer (1.2%, n=3), and breast cancer (0.4%, n=1). Of the 9 patients with occult neoplasms, 5 (2.0%) were identified from the 178 breast cancer patients, and 4 (1.6%) were detected in 65 healthy mutation carriers. During the median follow-up period of 36.7 months (interquartile range, 25.9-71.4), 1 (0.4%) BRCA1 PV carrier with no precursor lesions at RRSO developed primary peritoneal carcinomatosis after 30.1 months.Women with HRR gene mutations PV/LPV who undergo RRSO are at a risk of detecting occult neoplasms, with a of 3.5%. Even in the absence of precursor lesions during RRSO, there was a cumulative risk of peritoneal carcinomatosis development, emphasizing the need for continued surveillance.© 2025. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology.